Going on Trial rounds up new developments in autism-related drug trials. This month we’re revisiting decade-old data from a trial of arbaclofen for fragile X syndrome and looking into a new implant-based approach to quelling seizures, among other treatment strategies.

The investigational drug arbaclofen makes autistic people’s brains respond to a visual task more like non-autistic people’s brains do.

A test of binocular rivalry may distinguish between autism subtypes and help researchers screen the efficacy of certain drugs.

A brain region that orchestrates responses to social cues and aids decision-making may be off tempo in autism.

New results from brain scans of adults with autism are at odds with the popular theory that the condition involves weak brakes on brain activity.